Advances in cell-type specific delivery of RNAi-based therapeutics

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

RNAi-based gene silencing mechanisms have emerged as indispensible tools for experimentally induced, sequence-specific inhibition of gene expression. The translation of these technologies for therapeutic applications has required the development of clinically feasible delivery strategies that facilitate the uptake of the siRNAs by specific cell type(s) and tissues. This feature review focuses on the progress made in the targeted delivery of siRNAs and the challenges encountered in the development of safe and effective therapeutic silencing agents.

Original languageEnglish
Pages (from-to)325-331
Number of pages7
JournalIDrugs
Volume13
Issue number5
StatePublished - May 1 2010

Fingerprint

Gene Silencing
RNA Interference
Technology
Gene Expression
Therapeutics
RNAi Therapeutics

Keywords

  • Cell type-specific delivery
  • RNAi
  • SiRNA
  • Therapeutic gene silencing

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Advances in cell-type specific delivery of RNAi-based therapeutics. / Dykxhoorn, Derek M.

In: IDrugs, Vol. 13, No. 5, 01.05.2010, p. 325-331.

Research output: Contribution to journalArticle

@article{2737669e32d24cbcaa117221b93b98c0,
title = "Advances in cell-type specific delivery of RNAi-based therapeutics",
abstract = "RNAi-based gene silencing mechanisms have emerged as indispensible tools for experimentally induced, sequence-specific inhibition of gene expression. The translation of these technologies for therapeutic applications has required the development of clinically feasible delivery strategies that facilitate the uptake of the siRNAs by specific cell type(s) and tissues. This feature review focuses on the progress made in the targeted delivery of siRNAs and the challenges encountered in the development of safe and effective therapeutic silencing agents.",
keywords = "Cell type-specific delivery, RNAi, SiRNA, Therapeutic gene silencing",
author = "Dykxhoorn, {Derek M}",
year = "2010",
month = "5",
day = "1",
language = "English",
volume = "13",
pages = "325--331",
journal = "IDrugs : the investigational drugs journal",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Advances in cell-type specific delivery of RNAi-based therapeutics

AU - Dykxhoorn, Derek M

PY - 2010/5/1

Y1 - 2010/5/1

N2 - RNAi-based gene silencing mechanisms have emerged as indispensible tools for experimentally induced, sequence-specific inhibition of gene expression. The translation of these technologies for therapeutic applications has required the development of clinically feasible delivery strategies that facilitate the uptake of the siRNAs by specific cell type(s) and tissues. This feature review focuses on the progress made in the targeted delivery of siRNAs and the challenges encountered in the development of safe and effective therapeutic silencing agents.

AB - RNAi-based gene silencing mechanisms have emerged as indispensible tools for experimentally induced, sequence-specific inhibition of gene expression. The translation of these technologies for therapeutic applications has required the development of clinically feasible delivery strategies that facilitate the uptake of the siRNAs by specific cell type(s) and tissues. This feature review focuses on the progress made in the targeted delivery of siRNAs and the challenges encountered in the development of safe and effective therapeutic silencing agents.

KW - Cell type-specific delivery

KW - RNAi

KW - SiRNA

KW - Therapeutic gene silencing

UR - http://www.scopus.com/inward/record.url?scp=77953222633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953222633&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 325

EP - 331

JO - IDrugs : the investigational drugs journal

JF - IDrugs : the investigational drugs journal

SN - 1369-7056

IS - 5

ER -